Aehr Test Systems' Earnings: A Quarter of Caution and Calculated Risks

Fiscal Fourth Quarter Financial Snapshot

In a display that might leave investors scratching their heads, Aehr reported net revenue of $14.1 million for the fourth quarter, a decline from the $16.6 million seen in the same period last year. The EPS consensus anticipated a smoother ride, but the actual GAAP net loss of $(2.9) million, translating to $(0.10) per diluted share, certainly wasn't the news investors hoped to hear.

Last year, the same quarter boasted a GAAP net income of $23.9 million, buoyed by a tax benefit of approximately $20.7 million. This year, however, the numbers tell a different story—one filled with caution and perhaps a hint of optimism in the face of adversity.

Non-GAAP Metrics Tell a Complicated Tale

When we pivot to non-GAAP metrics, the narrative doesn’t get much clearer. Aehr’s non-GAAP net loss was $(0.2) million, or $(0.01) per diluted share, compared to a non-GAAP net income of $24.7 million, or $0.84 per diluted share, from the previous year’s fourth quarter. This year’s results included adjustments that stripped out stock-based compensation and acquisition-related costs, painting a picture that’s as murky as a foggy morning in San Francisco.

Bookings and Backlog: A Mixed Outlook

Bookings for the quarter stood at $11.1 million, while the backlog as of May 30, 2025, was reported at $15.2 million. Adding a sprinkle of optimism, the effective backlog, which accounts for bookings since then, rose to $16.3 million. But will this be enough to counterbalance the revenue forecast that seems to be sliding downwards?

Fiscal Year Financial Results: The Broader Picture

Looking at the full fiscal year, Aehr recorded net revenue of $59.0 million, down from $66.2 million in fiscal 2024. The GAAP net loss for the year was $(3.9) million, or $(0.13) per diluted share, again contrasting sharply with a net income of $33.2 million, or $1.12 per diluted share from the prior year. These numbers suggest that while Aehr is still in the game, it certainly isn't enjoying a winning streak.

On a non-GAAP basis, the company managed to post a net income of $4.6 million, or $0.15 per diluted share, but this is a far cry from the $35.8 million, or $1.21 per diluted share, seen in fiscal 2024. Cash used in operating activities clocked in at $7.4 million for fiscal 2025, indicating a need for tighter financial stewardship as the company reassesses its operating model.

What Lies Ahead for Aehr Test Systems?

As Aehr navigates these financial waters, the semiconductor industry continues to evolve, with increasing competition and technological advancements. The decline in revenues and net income raises questions about its strategy moving forward. Will Aehr pivot to seize new opportunities, or will it remain anchored in its current offerings?

With the total cash, cash equivalents, and restricted cash falling to $26.5 million from $31.4 million at the end of February 2025, the company faces pressure to innovate and adapt. Investors will be watching closely to see if Aehr can turn around this earnings surprise and reposition itself to capture a larger share of the growing semiconductor market.